KR100771286B1 - 퀴놀리닐 및 벤조티아졸릴 ｐｐａｒ-감마 조절물질 - Google Patents
퀴놀리닐 및 벤조티아졸릴 ｐｐａｒ-감마 조절물질 Download PDFInfo
- Publication number
- KR100771286B1 KR100771286B1 KR1020027017927A KR20027017927A KR100771286B1 KR 100771286 B1 KR100771286 B1 KR 100771286B1 KR 1020027017927 A KR1020027017927 A KR 1020027017927A KR 20027017927 A KR20027017927 A KR 20027017927A KR 100771286 B1 KR100771286 B1 KR 100771286B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- chloro
- group
- phenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CCCC=C(CC*=C(Cc(c(N)c1)c(*)cc1[N+]([O-])=O)N1)C1=C* Chemical compound CCCC=C(CC*=C(Cc(c(N)c1)c(*)cc1[N+]([O-])=O)N1)C1=C* 0.000 description 9
- ZYSFXQQFCNAVQX-UHFFFAOYSA-N CC(C(C=C1)Nc2nc3c(C)ccc(C)c3[s]2)(C=C1[N+]([O-])=O)Cl Chemical compound CC(C(C=C1)Nc2nc3c(C)ccc(C)c3[s]2)(C=C1[N+]([O-])=O)Cl ZYSFXQQFCNAVQX-UHFFFAOYSA-N 0.000 description 1
- AMNPNQPJCREQBE-UHFFFAOYSA-N N#CCc1cc(cccc2)c2nc1 Chemical compound N#CCc1cc(cccc2)c2nc1 AMNPNQPJCREQBE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Quinoline Compounds (AREA)
- Holo Graphy (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21481000P | 2000-06-28 | 2000-06-28 | |
| US60/214,810 | 2000-06-28 | ||
| PCT/US2001/020756 WO2002000633A1 (en) | 2000-06-28 | 2001-06-27 | Quinolinyl and benzothiazolyl ppar-gamma modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20030024713A KR20030024713A (ko) | 2003-03-26 |
| KR100771286B1 true KR100771286B1 (ko) | 2007-10-29 |
Family
ID=22800496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027017927A Expired - Lifetime KR100771286B1 (ko) | 2000-06-28 | 2001-06-27 | 퀴놀리닐 및 벤조티아졸릴 ｐｐａｒ-감마 조절물질 |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1296967B1 (https=) |
| JP (1) | JP4515026B2 (https=) |
| KR (1) | KR100771286B1 (https=) |
| CN (1) | CN1243741C (https=) |
| AT (1) | ATE327984T1 (https=) |
| AU (2) | AU2001271637B2 (https=) |
| BR (1) | BRPI0112115B8 (https=) |
| CA (1) | CA2412723C (https=) |
| CY (1) | CY1105126T1 (https=) |
| CZ (1) | CZ302982B6 (https=) |
| DE (1) | DE60120163T2 (https=) |
| DK (1) | DK1296967T3 (https=) |
| EA (1) | EA005976B1 (https=) |
| ES (1) | ES2265435T3 (https=) |
| HK (1) | HK1052351B (https=) |
| HU (1) | HUP0301482A3 (https=) |
| IL (2) | IL153461A0 (https=) |
| MX (1) | MXPA02012708A (https=) |
| NO (1) | NO325448B1 (https=) |
| NZ (1) | NZ523229A (https=) |
| PL (1) | PL214670B1 (https=) |
| PT (1) | PT1296967E (https=) |
| SK (1) | SK288236B6 (https=) |
| WO (1) | WO2002000633A1 (https=) |
| ZA (1) | ZA200210283B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| WO2001082916A2 (en) | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1435946B8 (en) | 2001-09-14 | 2013-12-18 | Amgen Inc. | Linked biaryl compounds |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| EP2399903A1 (en) | 2002-05-24 | 2011-12-28 | Millennium Pharmaceuticals, Inc. | Ccr9 inhibitors and methods of use thereof |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| US6939885B2 (en) | 2002-11-18 | 2005-09-06 | Chemocentryx | Aryl sulfonamides |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MXPA05008600A (es) | 2003-02-13 | 2005-11-04 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
| CA2521189A1 (en) * | 2003-04-11 | 2004-10-28 | Gabor Tigyi | Lysophosphatidic acid analogs and inhibition of neointima formation |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| EP1630152A4 (en) * | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| WO2006020830A2 (en) * | 2004-08-12 | 2006-02-23 | Amgen Inc. | Bisaryl-sulfonamides |
| CA2614746C (en) | 2005-07-09 | 2011-05-10 | Astrazeneca Ab | Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| CA2637373A1 (en) | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| EP1976377A4 (en) | 2006-01-25 | 2010-06-23 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| US20090176885A1 (en) | 2006-02-02 | 2009-07-09 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CA2641673A1 (en) * | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| TW200820970A (en) * | 2006-09-21 | 2008-05-16 | Nicholas Piramal India Ltd | Compounds for the treatment of metabolic disorders |
| WO2012162463A1 (en) * | 2011-05-25 | 2012-11-29 | Janssen Pharmaceutica Nv | Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation |
| EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| CN109651208B (zh) * | 2017-10-10 | 2022-01-04 | 中国科学院上海药物研究所 | N-芳基磺酰胺类化合物，其药物组合物及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038845A1 (en) * | 1998-01-29 | 1999-08-05 | Tularik Inc. | Ppar-gamma modulators |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3632329A1 (de) * | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| IL147308A0 (en) * | 1999-06-30 | 2002-08-14 | Tularik Inc | Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same |
-
2001
- 2001-06-27 KR KR1020027017927A patent/KR100771286B1/ko not_active Expired - Lifetime
- 2001-06-27 HK HK03104574.3A patent/HK1052351B/en not_active IP Right Cessation
- 2001-06-27 CA CA2412723A patent/CA2412723C/en not_active Expired - Lifetime
- 2001-06-27 AU AU2001271637A patent/AU2001271637B2/en not_active Expired
- 2001-06-27 WO PCT/US2001/020756 patent/WO2002000633A1/en not_active Ceased
- 2001-06-27 CZ CZ20024197A patent/CZ302982B6/cs not_active IP Right Cessation
- 2001-06-27 IL IL15346101A patent/IL153461A0/xx active IP Right Grant
- 2001-06-27 ES ES01950669T patent/ES2265435T3/es not_active Expired - Lifetime
- 2001-06-27 DE DE60120163T patent/DE60120163T2/de not_active Expired - Lifetime
- 2001-06-27 DK DK01950669T patent/DK1296967T3/da active
- 2001-06-27 SK SK1835-2002A patent/SK288236B6/sk not_active IP Right Cessation
- 2001-06-27 AU AU7163701A patent/AU7163701A/xx active Pending
- 2001-06-27 EP EP01950669A patent/EP1296967B1/en not_active Expired - Lifetime
- 2001-06-27 EA EA200300078A patent/EA005976B1/ru not_active IP Right Cessation
- 2001-06-27 NZ NZ523229A patent/NZ523229A/en not_active IP Right Cessation
- 2001-06-27 PL PL359996A patent/PL214670B1/pl unknown
- 2001-06-27 JP JP2002505381A patent/JP4515026B2/ja not_active Expired - Lifetime
- 2001-06-27 CN CNB018120172A patent/CN1243741C/zh not_active Expired - Lifetime
- 2001-06-27 BR BRPI0112115A patent/BRPI0112115B8/pt not_active IP Right Cessation
- 2001-06-27 PT PT01950669T patent/PT1296967E/pt unknown
- 2001-06-27 MX MXPA02012708A patent/MXPA02012708A/es active IP Right Grant
- 2001-06-27 HU HU0301482A patent/HUP0301482A3/hu unknown
- 2001-06-27 AT AT01950669T patent/ATE327984T1/de active
-
2002
- 2002-12-16 IL IL153461A patent/IL153461A/en unknown
- 2002-12-19 ZA ZA2002/10283A patent/ZA200210283B/en unknown
- 2002-12-20 NO NO20026156A patent/NO325448B1/no not_active IP Right Cessation
-
2006
- 2006-08-07 CY CY20061101099T patent/CY1105126T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038845A1 (en) * | 1998-01-29 | 1999-08-05 | Tularik Inc. | Ppar-gamma modulators |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100771286B1 (ko) | 퀴놀리닐 및 벤조티아졸릴 ｐｐａｒ-감마 조절물질 | |
| US6583157B2 (en) | Quinolinyl and benzothiazolyl modulators | |
| US6770648B2 (en) | Compounds for the modulation of PPARγ activity | |
| CA2377309C (en) | Compounds for the modulation of ppar.gamma. activity | |
| AU2001271637A1 (en) | Quinolinyl and benzothiazolyl ppar-gamma modulators | |
| CA2555914A1 (en) | Therapeutic modulation of ppar (gamma) activity | |
| US7960408B2 (en) | Quinolinyl and benzothiazolyl modulators | |
| AU779730B2 (en) | Compounds for the modulation of PPARgamma activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20021228 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20050329 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20060724 Patent event code: PE09021S01D |
|
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20061107 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20070212 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20070801 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20071023 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20071023 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20101020 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110921 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20121009 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20121009 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20131001 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20131001 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20141006 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20141006 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20150918 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150918 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20160921 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160921 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20170919 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170919 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20181001 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20181001 Start annual number: 12 End annual number: 12 |
|
| PC1801 | Expiration of term |
Termination date: 20211227 Termination category: Expiration of duration |